PMID- 27101149
OWN - NLM
STAT- MEDLINE
DCOM- 20170717
LR  - 20180214
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 45
DP  - 2016 Jun
TI  - The role of the Chaperonin containing t-complex polypeptide 1, subunit 8 (CCT8) 
      in B-cell non-Hodgkin's lymphoma.
PG  - 59-67
LID - S0145-2126(16)30050-9 [pii]
LID - 10.1016/j.leukres.2016.04.010 [doi]
AB  - The chaperonin containing t-complex polypeptide 1 (CCT) is known to mediate 
      folding of proteins. CCT, subunit 8 (CCT8), is the theta subunit of CCT complex 
      chaperonin. CCT8 has been reported to be dysregulated in several tumor tissues. 
      In this study, we investigated the role of CCT8 in B-cell non-Hodgkin's lymphoma 
      (NHL). Clinically, the expression levels of CCT8 in reactive lymphoid hyperplasia 
      (RLH) and B-cell NHL specimens were investigated using immunohistochemical 
      analysis. We found that CCT8 was highly expressed in proliferating germinal 
      center cells compared with the quiescent cells of the follicular mantle zone. 
      Furthermore, CCT8 was highly expressed in progressive lymphomas than in indolent 
      lymphomas. Kaplan-Meier curve showed that high expression of CCT8 was 
      significantly associated with shorter overall survival in patients with diffuse 
      large B-cell lymphoma. Moreover, we demonstrated that CCT8 could promote the 
      proliferation of B-cell NHL cells. In addition, we found that CCT8 could 
      accelerate the G1/S transition in B-cell NHL. Finally, we demonstrated that 
      overexpression of CCT8 could reverse cell adhesion-mediated drug resistance 
      (CAM-DR) phenotype. Our study may shed new insights into the important role of 
      CCT8 in cancer development.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Yin, Haibing
AU  - Yin H
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Miao, Xiaobing
AU  - Miao X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Wu, Yaxun
AU  - Wu Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Wei, Yingze
AU  - Wei Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Zong, Guijuan
AU  - Zong G
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Yang, Shuyun
AU  - Yang S
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Chen, Xudong
AU  - Chen X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Zheng, Guihua
AU  - Zheng G
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Zhu, Xinghua
AU  - Zhu X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Guo, Yan
AU  - Guo Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Li, Chunsun
AU  - Li C
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Chen, Yali
AU  - Chen Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China.
FAU - Wang, Yuchan
AU  - Wang Y
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Nantong University, Nantong 226001, Jiangsu, China. Electronic address: 
      wangyuchannt@126.com.
FAU - He, Song
AU  - He S
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong 226361, Jiangsu, China. Electronic address: hesongnt@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160411
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - EC 3.6.1.- (CCT8 protein, human)
RN  - EC 3.6.1.- (Chaperonin Containing TCP-1)
SB  - IM
MH  - Aged
MH  - Cell Adhesion
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Chaperonin Containing TCP-1/analysis/*physiology
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Germinal Center/chemistry/pathology
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Lymphoma, B-Cell/*chemistry/pathology
MH  - Male
MH  - Middle Aged
MH  - Survival Rate
OTO - NOTNLM
OT  - B-cell non-Hodgkin's lymphoma
OT  - CCT8
OT  - Cell adhesion-mediated drug resistance (CAM-DR)
OT  - Cell cycle
OT  - Proliferation
EDAT- 2016/04/22 06:00
MHDA- 2017/07/18 06:00
CRDT- 2016/04/22 06:00
PHST- 2016/02/05 00:00 [received]
PHST- 2016/04/05 00:00 [revised]
PHST- 2016/04/08 00:00 [accepted]
PHST- 2016/04/22 06:00 [entrez]
PHST- 2016/04/22 06:00 [pubmed]
PHST- 2017/07/18 06:00 [medline]
AID - S0145-2126(16)30050-9 [pii]
AID - 10.1016/j.leukres.2016.04.010 [doi]
PST - ppublish
SO  - Leuk Res. 2016 Jun;45:59-67. doi: 10.1016/j.leukres.2016.04.010. Epub 2016 Apr 
      11.